Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has provided an update on its on-market share buy-back program for its ordinary fully paid shares traded under the ASX code NEU. The latest filing, dated 6 May 2026, confirms that this announcement is an amendment to prior notifications and forms part of a series of daily buy-back updates.
The company reported that a total of 222,000 shares had been repurchased before the previous trading day, with an additional 31,900 shares bought back on the previous day as part of the ongoing on-market buy-back. This continued execution of the buy-back reflects Neuren’s active approach to capital management and may support its share price by reducing the volume of securities on issue.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.10 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a biopharmaceutical company listed on the ASX under the code NEU, with its primary securities being ordinary fully paid shares. The company operates in the pharmaceuticals sector, focusing on the development and commercialisation of drug therapies, and actively manages its capital structure through listed-equity transactions.
Average Trading Volume: 487,204
Technical Sentiment Signal: Sell
Current Market Cap: A$1.59B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.